Clinical Trials Logo

Agnogenic Myeloid Metaplasia clinical trials

View clinical trials related to Agnogenic Myeloid Metaplasia.

Filter by:
  • None
  • Page 1

NCT ID: NCT00506402 Completed - Clinical trials for Hematological Malignancies

A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies

NCT ID: NCT00255346 Completed - Clinical trials for Acute Myeloid Leukemia

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Start date: November 15, 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.

NCT ID: NCT00136409 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Start date: May 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.

NCT ID: NCT00088231 Completed - Clinical trials for Acute Myelogenous Leukemia

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Start date: July 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical research study is to find the highest safe doses of PTK 787 (vatalanib) and Gleevec (imatinib mesylate) that can be given to treat Chronic Myelogenous Leukemia-Blastic Phase (CML-BP), Refractory Acute Myelogenous Leukemia (AML), or Agnogenic Myeloid Metaplasia (AMM). Another goal is to see how effective this combination treatment is.